Open Access and Free to Publish in Asian Journal of Health Sciences

Reviews Open Access Logo

A review on etiopathology and outcome in pre-eclampsia

Sudhakara Babu Chelli 1, *
G Rachel Raveena 1
D Sudhakara Babu 1
P Jayasudha 1
  1. Department of Anatomy, Government Medical College, Nizamabad, Telangana, India
Correspondence to: Sudhakara Babu Chelli, Department of Anatomy, Government Medical College, Nizamabad, Telangana, India. Email: phucpham@sci.edu.vn.
Volume & Issue: Vol. 10 No. 1 (2024) | Page No.: 58 | DOI: 10.15419/ajhs.v10i1.530
Published: 2024-06-30

Online metrics


Statistics from the website

  • HTML Views: 239
  • PDF Views: 49
  • XML Views: 0

Statistics from Dimensions

Copyright The Author(s) 2017. This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. 

Abstract

Preeclampsia is a major cause of premature birth, intrauterine growth restriction (IUGR), maternal and fetal morbidity, perinatal mortality, and accounts for 15–20% of maternal mortality cases. It is categorized as mild, moderate, or severe. Risk factors include obesity, primigravida status, placental abnormalities, multiple gestation, chronic renal disease, and family history, among other factors. Endothelial dysfunction and vasospasm are recognized as the underlying pathologies contributing to systemic vascular involvement. According to current research, vascular endothelial dysfunction arises from a deficiency in vascular endothelial growth factor (VEGF). This VEGF deficiency in preeclampsia is linked to elevated levels of soluble fms-like tyrosine kinase-1 (sFlt1), which antagonizes VEGF signaling. Placental ischemia and hypoxia represent the final pathway in the pathophysiology of preeclampsia, triggering the release of vasoactive substances into maternal circulation and resulting in endothelial dysfunction that manifests as clinical signs and symptoms.

Introduction

Preeclampsia (PE) is characterized by elevated blood pressure and excessive levels of protein in the urine that begin at 20 weeks of gestation. Its overall prevalence rate is 5-8%, which is a major cause of Intrauterine Growth Restriction (IUGR), preterm birth, morbidity, perinatal fatalities, and 15–20% of maternal mortality 1, 2. PE predicts a greater risk of cardiovascular and metabolic disorders as age advances, which may necessitate lifestyle counseling and intervention. Preeclampsia remains the most common cause of maternal and perinatal death and morbidity 3, 4. If blood pressure and proteinuria rise significantly, or if there are indications of end-organ damage, it is termed severe. There are no well-established primary prevention strategies. Despite evidence-based management, prevention measures, and screening tools are limited to symptomatic treatment, and delivery remains the only cure 5. Despite extensive research, the etiology remains unclear. There has been no significant change in preeclampsia treatment in over 50 years 6.

Classification of PE

For management purposes, PE is categorized based on blood pressure (BP) levels. Proteinuria, on the other hand, is more important than blood pressure in predicting fetal outcome. Classification by Yorkshire series based on severity forms basis for PE classification.

Causes of PE

Risk factors are basically classified into immunological and genetic9, 10 shown in Table 1.

Table 1

Preeclampsia-risk factors

Family history

Obesity

Primigravida

Thrombophilia

Placental abnormalities

Pre-existing vascular disease

New parity

Prolonged pregnancy interval

Multiple gestation

Chronic renal disease

Other risk factors also include vision abnormalities, shortness of breath, renal dysfunction, decreased liver function, edema and low platelet count.

Etiopathogenesis of PE

Under normal circumstances, endovascular trophoblasts penetrate the spiral arterioles of the uteroplacental bed and remodel them into large-diameter arteries with high capacitance and unrestricted blood flow11. Aberrant spiral arterial remodeling in pregnant women with a hypertensive disorder was first noticed and studied more than five decades ago 12. It has now been discovered to be the main cause of gestational hypertension, intrauterine growth restriction, and preeclampsia in pregnancies13. Atypical placentation has placental hypoperfusion as a cause as well as an outcome14, 15. In placental tissue, atherosclerosis, thrombosis, arteriosclerosis, fibrinoid necrosis, and infarction are the late pathological changes observed, which correlate with ischemia16. Endothelial dysfunction and vasospasm continue to be the underlying pathologies that affect all vessels. The development of eclampsia/preeclampsessa is independent of blood pressure levels17.

Pathophysiology

Although the primary pathology leading to preeclampsia remains unknown, the pathological changes are well-documented. Since the removal of the placenta is necessary to alleviate the symptoms, it always plays a significant role in the etiology of preeclampsia (PE) 18, 19. Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) are two angiogenic factors thought to be involved, according to recent research. Current molecular studies suggest that a reduction in VEGF causes dysfunction of the vascular endothelium in PE. The mechanism behind the inhibition of VEGF production in PE is attributed to elevated levels of sFlt-1, a potent inhibitor of VEGF production 20, 21, 22.

In PE, endothelial dysfunction results from an antiangiogenic state mediated by soluble endoglin, associated with lower levels of PlGF and VEGF, and high levels of sFlt-1. The placenta produces large amounts of sFlt-1, but in preeclampsia, an additional source of production is the circulating mononuclear cells 23, 24. In women with PE, higher levels of circulating sFlt-1 have been reported, which may precede the onset of PE, and the levels of sFlt-1 might correlate with the severity of PE 25, 26.

A key mediator in the development of PE is sFlt-127. The link between the occurrence of PE and the adaptive immune response is inflammation28. Placental DNA released into fetal and maternal circulation plays a major role in the characteristic inflammation associated with PE 29. The link between PE and maternal infection revealed that women with periodontal disease and urinary tract infections are at an increased risk of PE30, 31, 32. Most data suggest that both maternal and paternal genes are responsible for the development of placental abnormalities and subsequent PE33. The onset of the disease is likely influenced by genetic factors 34, 35. The final pathogenesis pathways of PE include ischemia and placental hypoxia, which release vasoactive substances into maternal circulation and cause endothelial cell dysfunction, leading to the signs and symptoms of PE 36, 37.

Maternal Outcome

The rates of adverse perinatal and maternal outcomes between primigravida and multigravida pregnancies showed no significant difference 38. The most common causes of maternal death are permanent neurological sequelae due to ischemia or cerebral hemorrhage, accounting for 0-14% of maternal mortality rates39. Additionally, 2-3% of women with preeclampsia experience complications due to eclampsia, which may lead to maternal morbidity and mortality 40.

Fetal Outcome

Intrauterine growth restriction, intrauterine death, asphyxia, and prematurity are consequences based on the duration and severity of the disease and the degree of proteinuria. Belay Tolu L et al. observed a 1.7% stillbirth rate, 2.27% neonatal death rate, 12% incidence of IUGR, and an 18.2% rate of preterm birth in their study 38. Oligohydramnios and IUGR are the primary consequences in preeclampsia due to decreased placental perfusion41. Adverse perinatal events are due to the underlying pathology of the placenta. In preeclamptic mothers who deliver preterm, aberrant placental weight indicates an adverse neonatal outcome 42. Preterm delivery owing to HELLP syndrome or preeclampsia was associated with necrotizing enterocolitis requiring surgery, a lower incidence of intracerebral hemorrhage, periventricular leukomalacia, and death when compared to other causes of preterm birth after adjustment for confounding variables 43. Neonatal death and morbidity in severe preeclampsia are linked to gestational age rather than the absence or presence of the HELLP syndrome44.

Conclusion

In spite of several theories and documented mechanisms, the etiology of preeclampsia remains unclear. It is a principal cause of maternal mortality and morbidity that affects both the mother and fetus. Its etiology presents a challenge that requires thorough research to understand its complexity. Translational research is now required to demonstrate how these developing concepts might be applied to aid in early diagnosis and treatment.

Abbreviations

BP (Blood Pressure), DNA (Deoxyribonucleic acid), HELLP (Hemolysis, Elevated Liver enzymes, and Low Platelet count), IUGR (Intrauterine Growth Restriction), mm Hg (millimeters of mercury), PE (Preeclampsia), PlGF (Placental Growth Factor), sFlt-1 (Soluble fms-like tyrosine kinase-1), and VEGF (Vascular Endothelial Growth Factor).

Acknowledgments

None.

Author’s contributions

All authors significaly contributed to this work, read and approved the final manuscript.

Funding

None

Availability of data and materials

None.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

  1. . Gathiram P, Moodley JJ. Pre-eclampsia: its pathogenesis and pathophysiolgy: review articles. Cardiovascular journal of Africa. 2016 Mar 1;27(2):71-8. :
  2. . Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. The Lancet. 2005 Feb 26;365(9461):785-99. :
  3. . de Swiet M. Maternal mortality: confidential enquiries into maternal deaths in the United Kingdom. Am J Obstet Gynecol . 2000; 182: 760-766 .
  4. . Steegers EA, Von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. The Lancet. 2010 Aug 21;376(9741):631-44. :
  5. . Bell MJ. A historical overview of preeclampsia‐eclampsia. Journal of Obstetric, Gynecologic & Neonatal Nursing. 2010 Sep 1;39(5):510-8. :
  6. . Noris M, Perico N, Remuzzi G. Mechanisms of disease: pre-eclampsia. Nature clinical practice Nephrology. 2005 Dec;1(2):98-114. :
  7. . Tuffnell DJ, Jankowicz D, Lindow SW, Lyons G, Mason GC, Russell IF, Walker JJ; Yorkshire Obstetric Critical Care Group. Outcomes of severe pre-eclampsia/eclampsia in Yorkshire 1999/2003. BJOG. 2005 Jul;112(7):875-80. :
  8. . Jido TA, Yakasai IA. Preeclampsia: a review of the evidence. Annals of African medicine. 2013 Apr 1;12(2):75. :
  9. . DC Dutta's textbook of Obstetrics .7th Edition ,2014: 219-240. :
  10. . Khalil G, Hameed A. Preeclampsia: pathophysiology and the maternal-fetal risk. J Hypertens Manag. 2017;3(1):1-5. :
  11. . Lim KH, Zhou Y, Janatpour M, McMaster M, Bass K, Chun SH, Fisher SJ. Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia. The American journal of pathology. 1997 Dec;151(6):1809. :
  12. . Brosens I. A study of the spiral arteries of the decidua basalis in normotensive and hypertensive pregnancies. BJOG: An International Journal of Obstetrics & Gynaecology. 1964 Apr;71(2):222-30. :
  13. . Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biology of reproduction. 2003 Jul 1;69(1):1-7. :
  14. . Cheng MH, Wang PH. Placentation abnormalities in the pathophysiology of preeclampsia. Expert review of molecular diagnostics. 2009 Jan 1;9(1):37-49. :
  15. . Alasztics B, Kukor Z, Pánczél Z, Valent S. The pathophysiology of preeclampsia in view of the two-stage model. Orvosi hetilap. 2012 Jul 1;153(30):1167-76. :
  16. . MAQUEO M, AZUELA JC. Placental pathology in eclampsia and preeclampsia. Obstetrics & Gynecology. 1964 Sep 1;24(3):350-6. :
  17. . Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clinical Journal of the American Society of Nephrology. 2016 Jun 6;11(6):1102-13. :
  18. . Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: An endothelial cell disorder. International Journal of Gynecology & Obstetrics. 1990 Jul;32(3):299-. :
  19. . Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009 Mar 1;30:32-7. :
  20. . Bills VL, Salmon AH, Harper SJ, Overton TG, Neal CR, Jeffery B, et al. Impaired vascular permeability regulation caused by the VEGF 165 b splice variant in pre-eclampsia. BJOG 2011;118:1253-61. :
  21. . Kappers MH, Smedts FM, Horn T, van Esch JH, Sleijfer S, Leijten F, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 2011;58:295-302. :
  22. . Ahmad S, Hewett PW, Al-Ani B, Sissaoui S, Fujisawa T, Cudmore MJ, et al. Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis. Vasc Cell 2011;3:15. :
  23. S. Venkatesha. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature Medicine, vol. 12, no. 6, pp. 642-649, 2006. :
  24. D. Hui. Combinations of maternal serum markers to predict preeclampsia, small for gestational age, and stillbirth: a systematic review. Journal of Obstetrics and Gynaecology Canada, vol. 34, no. 2, pp. 142-153, 2012. :
  25. C. E. Powe. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation, vol. 123, no. 24, pp. 2856-2869, 2011. :
  26. V. L. Clifton. Review: the feto-placental unit, pregnancy pathology and impact on long term maternal health. Placenta, vol. 33, pp. S37-S41, 2012 . :
  27. . Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. The Journal of clinical investigation. 2003 Mar 1;111(5):649-58. :
  28. T. G. Wegmann. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunology Today, vol. 14, no. 7, pp. 353-356, 1993. :
  29. . LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Current hypertension reports. 2007 Dec;9(6):480-5. :
  30. . Haggerty CL, Klebanoff MA, Panum I, Uldum SA, Bass DC, Olsen J, Roberts JM, Ness RB. Prenatal Chlamydia trachomatis infection increases the risk of preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health. 2013 Jul 1;3(3):151-4. :
  31. . Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. American journal of obstetrics and gynecology. 2008 Jan 1;198(1):7-22. :
  32. . Easter SR, Cantonwine DE, Zera CA, Lim KH, Parry SI, McElrath TF. Urinary tract infection during pregnancy, angiogenic factor profiles, and risk of preeclampsia. American journal of obstetrics and gynecology. 2016 Mar 1;214(3):387-e1. :
  33. . Dekker G, Robillard PY, Roberts C. The etiology of preeclampsia: the role of the father. Journal of reproductive immunology. 2011 May 1;89(2):126-32. :
  34. . Cox B. Bioinformatic approach to the genetics of preeclampsia. Obstetrics & Gynecology. 2014 Sep 1;124(3):633. :
  35. . Oudejans CB, van Dijk M, Oosterkamp M, Lachmeijer A, Blankenstein MA. Genetics of preeclampsia: paradigm shifts. Human genetics. 2007 Jan 1;120(5):607-12. :
  36. . Rampersad R, Nelson DM. Trophoblast biology, responses to hypoxia and placental dysfunction in preeclampsia. Front Biosci. 2007 Jan 1;12(2447):56. :
  37. . Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation. 2002 Jan 1;9(3):147-60. :
  38. . Belay Tolu L, Yigezu E, Urgie T, Feyissa GT. Maternal and perinatal outcome of preeclampsia without severe feature among pregnant women managed at a tertiary referral hospital in urban Ethiopia. Plos one. 2020 Apr 9;15(4):e0230638. :
  39. . Helewa ME, Burrows RF, Smith J, Williams K, Brain P, Rabkin SW. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. Cmaj. 1997 Sep 15;157(6):715-25. :
  40. . Ahmed A, Rezai H, Broadway-Stringer S. Evidence-based revised view of the pathophysiology of preeclampsia. Hypertension: from basic research to clinical practice. 2016:355-74. :
  41. . Weiner E, Schreiber L, Grinstein E, Feldstein O, Rymer-Haskel N, Bar J, Kovo M. The placental component and obstetric outcome in severe preeclampsia with and without HELLP syndrome. Placenta. 2016 Nov 1; 47:99-104. :
  42. . Vinnars MT, Nasiell J, Holmström G, Norman M, Westgren M, Papadogiannakis N. Association between placental pathology and neonatal outcome in preeclampsia: a large cohort study. Hypertension in pregnancy. 2014 May 1;33(2):145-58. :
  43. . Bossung V, Fortmann MI, Fusch C, Rausch T, Herting E, Swoboda I, Rody A, Härtel C, Göpel W, Humberg A. Neonatal outcome after preeclampsia and HELLP syndrome: a population-based cohort study in Germany. Frontiers in Pediatrics. 2020;8. :
  44. . Abramovici D, Friedman SA, Mercer BM, Audibert F, Kao L, Sibai BM. Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter?. American journal of obstetrics and gynecology. 1999 Jan 1;180(1):221-5. :

Comments